Immune Checkpoint Inhibitors Market
DelveInsight's "Immune Checkpoint Inhibitors (ICI) Competitive Landscape, and Market Forecast – 2034" report delivers an in-depth understanding of the Immune Checkpoint Inhibitors therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Immune Checkpoint Inhibitors market report provides current treatment practices, emerging drugs, Immune Checkpoint Inhibitors market share of the individual therapies, current and forecasted Immune Checkpoint Inhibitors market Size from 2020 to 2034 segmented by seven major markets. The Report also covers current Immune Checkpoint Inhibitors treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
|
Study Period |
2020 to 2034 |
|
Forecast Period |
2024-2034 |
|
Geographies Covered |
|
|
Immune Checkpoint Inhibitors Market |
|
|
Immune Checkpoint Inhibitorss Market Size | |
|
Immune Checkpoint Inhibitors Companies |
Regeneron Pharmaceuticals Inc., AstraZeneca PLC, Eli Lilly and Company, Sanofi, BeiGene Ltd, Bristol-Myers Squibb Company, Merck & Co, F. Hoffmann-La Roche AG, Shanghai Jhunsi Biosciences Ltd, GlaxoSmithKline PLC, Immutep Ltd, and others. |
|
Immune Checkpoint Inhibitors Segmentation By Type |
|
Immune Checkpoint Inhibitors Treatment Market
The DelveInsight’s Immune Checkpoint Inhibitors market report gives a thorough understanding of Immune Checkpoint Inhibitors by including details such definition, types, mechanisms, applications, routes of administration, and treatment. Cancer immunotherapy harnesses the patient’s own immune system to fight against cancer, distinguishing immunotherapy from conventional cancer therapies, which directly target the tumor cells. Immune checkpoints are pathways with inhibitory or stimulatory features that maintain self-tolerance and assist with immune response. Well-described checkpoints are inhibitory in nature and include the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4), programmed cell death receptor-1 (PD-1), and programmed cell death ligand-1 (PD-L1).
The current scenario holds numerous challenges for the further progress. One of the major challenge is scantiness in identification of the major biomarkers generating a need for distinct clinical study designs for the evaluation of efficacy.
New immune-checkpoints, with either stimulatory or inhibitory functions are emerging with key roles in regulating T cell response but also affecting other crucial effectors belonging to the innate immune response (e.g., natural killer). The advancements in the Immune Checkpoint Inhibitors generates interest in several targets such as TIGIT, ICOS, OX-40, LAG-3, TIM-3, B7-H3, etc.
Immune Checkpoint Inhibitors Drug Chapters
The drug chapter segment of the Immune Checkpoint Inhibitors report encloses the detailed analysis of Immune Checkpoint Inhibitors marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Immune Checkpoint Inhibitors clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Immune Checkpoint Inhibitors Marketed Drugs
TECENTRIQ (Atezolizumab): Genetech
It is a checkpoint inhibitor that targets the PD-1/PD-L1 pathway; approved for the treatment of patients with bladder cancer, breast cancer, liver cancer, lung cancer, and melanoma.
BAVENCIO (avelumab): Pfizer
It is a checkpoint inhibitor that targets the PD-1/PD-L1 pathway; approved for subsets of patients with bladder cancer, kidney cancer, and Merkel cell carcinoma, a type of skin cancer.
LIBTAYO (cemiplimab): Regenron and Sanofi
It is a checkpoint inhibitor that targets the PD-1/PD-L1 pathway; approved for subsets of patients with cutaneous squamous cell carcinoma, basal cell carcinoma, and lung cancer.
JEMPERLI (dostarlimab): GlaxoSmithKline
It is a checkpoint inhibitor that targets the PD-1 pathway; approved for subsets of patients with uterine (endometrial) cancer.
IMFINZI (durvalumab): AstraZeneca
It is a checkpoint inhibitor that targets the PD-1/PD-L1 pathway; approved for subsets of patients with bladder cancer and lung cancer.
YERVOY (ipilimumab): Bristol-Myers Squibb
It is a checkpoint inhibitor that targets the CTLA-4 pathway; approved for subsets of patients with melanoma, mesothelioma, liver cancer, and lung cancer.
OPDIVO (nivolumab): Bristol-Myers Squibb
It is a checkpoint inhibitor that targets the PD-1/PD-L1 pathway; approved for subsets of patients with bladder cancer, colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, lymphoma, melanoma, and mesothelioma.
KEYTRUDA (pembrolizumab): Merck
It is a checkpoint inhibitor that targets the PD-1/PD-L1 pathway; approved for subsets of patients with bladder cancer, breast cancer, cervical cancer, colorectal cancer, cutaneous squamous cell carcinoma, esophageal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, lymphoma, melanoma, Merkel cell carcinoma, and stomach cancer. It is also approved to treat subsets of patients with cancers of any type that present with certain genetic mutations (MSI-H, dMMR, or TMB-H).
OPDUALAG (relatlimab/nivolumab): Bristol-Myers Squibb
It is a new, first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as a single intravenous infusion, is the first LAG-3 inhibitor which has been granted approval by the FDA in March 2022, for the treatment of adult and pediatric patients of 12 years of age or older, with unresectable or metastatic melanoma..
Note: Detailed Current therapies assessment will be provided in the full report of Immune Checkpoint Inhibitors
Immune Checkpoint Inhibitors Emerging Drugs
Fianlimab (REGN-3767) developed by Regeneron Pharmaceuticals, is a fully human monoclonal antibody targeting the immune checkpoint receptor LAG-3 on T cells. In melanoma, LAG-3 expression on cancer cells is associated with therapeutic resistance to PD-1 inhibitors. fianlimab is being investigated in combination with Regeneron's PD-1 inhibitor Libtayo to determine whether concurrent blockade of LAG-3 and PD-1 can help overcome this resistance and release the brakes on T cell activation.
Cobolimab (GSK-4069889), being developed by GlaxoSmithKline, is a monoclonal antibody against the inhibitory T-cell receptor, T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), with potential immune checkpoint inhibitory and antineoplastic activities.
Tiragolumab (RG-6058), being developed by Roche, is a novel immune checkpoint inhibitor with an intact Fc region, which selectively binds to TIGIT, a novel inhibitory immune checkpoint, which suppresses the immune response to cancer.
Ezabenlimab (BI-754091) being developed by Boehringer Ingelheim, is a monoclonal antibody antagonist of the key myeloid cell checkpoint inhibitor SIRPα. BI 765063 prevents the SIRPα ligand CD47, from binding to SIRPα thereby preventing cellular signalling that can reduce the anti-tumorigenic properties of myeloid cells such as macrophages and dendritic cells.
Note: Detailed emerging therapies assessment will be provided in the full report of Immune Checkpoint Inhibitors
Immune Checkpoint Inhibitors Market Outlook
Cancer immunotherapy (CI) is rapidly advancing and can now be considered to be the “fifth pillar” of cancer therapy, joining the ranks of surgery, cytotoxic chemotherapy, radiation, and targeted therapy. The CI which has sparked the most interest involves antibodies to inhibitory immune checkpoint molecules. The immune system is a network of cells, tissues, and organs that work together to protect the body from foreign invaders, such as bacteria or viruses. The key players in defending the body are a specific type of white blood cell (WBC) called lymphocytes. There are three major types of lymphocytes which include Natural killer (NK) cells, B cells, and T cells, respectively.
There are two main parts of the immune system, namely the humoral (also called antibody-mediated) immune response and the cell-mediated immune response. These two sides work together to keep the body safe from infections. As part of the humoral immune response, B-cells generate antibodies in the blood that helps fight off infections in the lymph or blood, and provide with lasting immunity to ward off future infections.
There are different types of immunotherapy which include checkpoint inhibitors, monoclonal antibody inhibitors, immune system modulators, vaccines, virus therapies, adoptive cell transfer and T-cell therapy and targeted therapies. Immunotherapy has become a major focus of anticancer therapy regimens and for a good reason: when it works, patients can have long-lasting antitumor immune responses that not only eradicate primary tumors, but metastasize lesions as well. Among all types of immunotherapy, Immune Checkpoint Inhibitors have been the most prominent ones in Oncology.
Other than already established targets like PD-1, PDL-1, CTLA-4; Immune Checkpoint Inhibitors currently under development pursues a diverse range of other immune targets, of which, some of the key targets are LAG-3, TIGIT, ICOS, OX-40, TIM-3, B7-H3, CD47-SIRPα receptor, and along with few others.
Key players such as Regeneron, Bristol-Myers-Squibb, Novartis, GlaxoSmithKline, Merck, Roche, and AstraZeneca, along with few others are involved in developing therapies for Immune Checkpoint Inhibitors. Concurrently, the increased funding for R&D by big players and organizations have enthused the scientists to put pedal on metal for further innovations.
According to DelveInsight, Immune Checkpoint Inhibitors market in 7MM is expected to witness a major change in the study period 2020-2034.
Analyst Commentary
The pipeline of Immune Checkpoint Inhibitors is very robust, many potential therapies are being investigated for the treatment of Immune Checkpoint Inhibitors, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.
The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the Immune Checkpoint Inhibitors market in the 7MM. Aside from that, the market size of Immune Checkpoint Inhibitors may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.
The market growth of Immune Checkpoint Inhibitors may offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.
Immune Checkpoint Inhibitors Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Immune Checkpoint Inhibitors market or expected to get launched in the market during the study period 2020-2034. The analysis covers Immune Checkpoint Inhibitors market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Note: Detailed emerging therapies assessment will be provided in full report of Immune Checkpoint Inhibitors.
Immune Checkpoint Inhibitors Pipeline Development Activities
The report provides insights into Immune Checkpoint Inhibitors clinical trials within Phase II and Phase III stage. It also analyses Immune Checkpoint Inhibitors key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Immune Checkpoint Inhibitors emerging therapies.
Reimbursement Scenario in Immune Checkpoint Inhibitors
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current market trends, we take KOLs and SMEs ' opinions working in the Immune Checkpoint Inhibitors domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Immune Checkpoint Inhibitors market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Immune Checkpoint Inhibitors Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Immune Checkpoint Inhibitors Market Report
- The report covers the descriptive overview of Immune Checkpoint Inhibitors, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
- Comprehensive insight has been provided into the Immune Checkpoint Inhibitors epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Immune Checkpoint Inhibitors are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Immune Checkpoint Inhibitors market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Immune Checkpoint Inhibitors market
Immune Checkpoint Inhibitors Report Highlights
- In the coming years, the Immune Checkpoint Inhibitors market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Immune Checkpoint Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Immune Checkpoint Inhibitors. The launch of emerging therapies will significantly impact the Immune Checkpoint Inhibitors market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Immune Checkpoint Inhibitors
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Immune Checkpoint Inhibitors Report Insights
- Immune Checkpoint Inhibitors Patient Population
- Immune Checkpoint Inhibitors Therapeutic Approaches
- Immune Checkpoint Inhibitors Pipeline Analysis
- Immune Checkpoint Inhibitors Market Size and Trends
- Immune Checkpoint Inhibitors Market Opportunities
- Impact of Upcoming Immune Checkpoint Inhibitors Therapies
Immune Checkpoint Inhibitors Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Key Cross Competition
- Highly Analyzed Market
- Immune Checkpoint Inhibitors Drugs Uptake
Immune Checkpoint Inhibitors Report Assessment
- Current Immune Checkpoint Inhibitors Treatment Practices
- Immune Checkpoint Inhibitors Unmet Needs
- Immune Checkpoint Inhibitors Pipeline Product Profiles
- Immune Checkpoint Inhibitors Market Attractiveness
- Immune Checkpoint Inhibitors Market Drivers
- Immune Checkpoint Inhibitors Market Barriers
Key Questions Answered In The Immune Checkpoint Inhibitors Market Report
Immune Checkpoint Inhibitors Market Insights:
- What was the Immune Checkpoint Inhibitors drug class share (%) distribution in 2020 and how it would look like in 2034?
- What would be the Immune Checkpoint Inhibitors total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
- What are the key findings of the market across 7MM and which country will have the largest Immune Checkpoint Inhibitors market size during the forecast period (2024-2034)?
- At what CAGR, the Immune Checkpoint Inhibitors market is expected to grow by 7MM during the forecast period (2024-2034)?
- What would be the Immune Checkpoint Inhibitors market outlook across the 7MM during the forecast period (2024-2034)?
- What would be the Immune Checkpoint Inhibitors market growth till 2034, and what will be the resultant market Size in the year 2034?
- How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?
Current Immune Checkpoint Inhibitors Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the Immune Checkpoint Inhibitors treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of Immune Checkpoint Inhibitors in the USA, Europe, and Japan?
- What are the Immune Checkpoint Inhibitors marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
- How many companies are developing therapies for the treatment of Immune Checkpoint Inhibitors?
- How many therapies are in-development by each company for Immune Checkpoint Inhibitors treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Immune Checkpoint Inhibitors treatment?
- What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Immune Checkpoint Inhibitors therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Immune Checkpoint Inhibitors and its status?
- What are the current challenges faced in drug development?
- What are the key designations that have been granted for the emerging therapies for Immune Checkpoint Inhibitors?
- What are the global historical and forecasted markets of Immune Checkpoint Inhibitors?
Reasons to buy Immune Checkpoint Inhibitors Market Forecast Report
- The report will help in developing business strategies by understanding trends shaping and driving the Immune Checkpoint Inhibitors market
- Organize sales and marketing efforts by identifying the best opportunities for Immune Checkpoint Inhibitors in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for the Immune Checkpoint Inhibitors market
- To understand the future market competition in the Immune Checkpoint Inhibitors market
Stay Updated with us for Recent Articles
